Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib

Edmund Ingham Investing Group Leader Follow Summary Zentalis Pharmaceuticals, Inc. earns a cautious Buy rating, driven by azenosertib’s potential in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). DENALI and ASPENOVA trials target accelerated and full FDA approval, with pivotal data expected in H1 '27 as a major catalyst. Recent $93m capital raise extends cash runway into 2028, supporting regulatory milestones and mitigating near-term funding risk. Success could drive ZNTL stock’s valuation toward $1bn, but failure in DENALI data may trigger a ~70% stock decline due to pipeline concentration. Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios. Learn More » Tom Werner/DigitalVision via Getty Images Investment Overview The last time I covered Zentalis Pharmaceuticals, Inc. ( ZNTL ) for Seeking Alpha, I issued a cautious Hold rating in an article published in November last year - the stock has, in fact, jumped in This article was written by Edmund Ingham 15.16K Followers Follow Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.